title: Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.
abstract: Mantle cell lymphoma (MCL) is an uncommon, incurable B-cell non-Hodgkin's lymphoma that afflicts the elderly. There is no standard course of treatment, with options varying from observation in asymptomatic patients to aggressive induction/consolidation regimens in younger patients with rapidly progressive disease. Emerging data regarding the role of the ubiquitin-proteasome system, B-cell receptor and mTOR signaling pathways, cell cycle regulation, and epigenetic and immune-modulation in the pathogenesis of MCL have resulted in the development of novel therapies, with a shift away from conventional cytotoxic chemotherapy to relatively less toxic, more targeted treatment. The challenge now is to determine the optimal sequence and combination of the various available and emerging therapies for use in patients with MCL.
authors.affiliation: Weill-Cornell Medical College, 525 East 68th Street, Box 403, New York, NY, 10065, USA, tzt2001@med.cornell.edu.
authors.forename: Tiffany
authors.initials: T
authors.lastname: Tang
authors.forename: Peter
authors.initials: P
authors.lastname: Martin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D044127:Epigenesis, Genetic / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000379:methods*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D011947:Receptors, Antigen, B-Cell / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D025801:Ubiquitin / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D011947:Receptors, Antigen, B-Cell; D025801:Ubiquitin; D058570:TOR Serine-Threonine Kinases; D046988:Proteasome Endopeptidase Complex